Thank you for donating!

You can donate using the following services.

News

  1. 17.01.18

    CTD Holdings’ European Clinical Trial Adopted by National Institute for Health Research of England

    CTD Holdings’ European Clinical Trial Adopted by National Institute for Health Research of England...

    Read more
  2. 04.01.18

    Research Study to Determine the rates of Parkinson Disease in Patients & Family Members with Niemann-Pick Disease (NPC and ASMD)

    Adina Wise is undertaking a research study to determine the rates of Parkinson disease in patients and family members with Niemann-Pick Disease (NPC and ASMD)...

    Read more
  3. 03.01.18

    Will Evans, NPUK Chair - Message for 2018

    NPUK Chair, Will Evans, gives his 2018 message...

    Read more
  4. 13.12.17

    CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol® Cyclo™

    CTD Holdings, Inc. today announced that it has received rare pediatric disease designation from the FDA for its Trappsol® Cyclo™ drug...

    Read more
  5. 20.11.17

    Orphazyme’s CEO, Anders Hinsby: Letter to NP-C Community

    A letter to the NPC community from Orphazyme’s CEO, Anders Hinsby. We are please to also provide translations (from English into German, French, Spanish, Italian, Polish) of this letter.

    Read more